youtube_live
Q3 2026 earnings • 7:30 AM tomorrow
See detailschevron_right
RVTY:NYSE
Revvity Inc
$151.60
arrow_downward
-3.44%(-5.40) 1D
$157.77
arrow_upward
+4.07% (+6.17)bedtimeAfter hours
Closed: Nov 2, 4:03:25 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RVTY...
Open
$160.07
High
$160.07
Low
$150.62
Mkt. cap
17.52B
Avg. vol.
1.91M
Volume
2.80M
52-wk high
$169.06
52-wk low
$81.22
Beta
1.06
Shares outstanding
111.59M
No. of employees
11K
Open
$160.07
High
$160.07
Low
$150.62
Mkt. cap
17.52B
Avg. vol.
1.91M
Volume
2.80M
52-wk high
$169.06
52-wk low
$81.22
Beta
1.06
Shares outstanding
111.59M
No. of employees
11K
News stories
From web sources and news partners
GuruFocus
·
1 hour ago
Revvity Inc (RVTY) Shares Fall 3.4% -- What GF Score of 70 Tells Investors
News Corp
·
3 hours ago
Revvity Inc. stock underperforms Monday when compared to competitors
Zacks
·
8 hours ago
Fair Isaac to Report Q4 Earnings: What's in Store for the Stock?
Profile
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.
In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY. Wikipedia
About Revvity Inc
CEOPrahlad Singh
Employees11K
Founded1947
HeadquartersWaltham, Massachusetts, United States
SectorHealth care
Websiterevvity.com
Analyst ratings
Based on 14 analysts giving stock ratings to RVTY in the past 3 months
Buy
Buy
4
Hold
10
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for RVTY in the last 3 months.
Highest
Current $151.60
$175.00 (+15.44%)
Average
$141.75 (-6.50%)
Lowest
$110.00 (-27.44%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Eve Burstein Bernstein | Hold | Reiterated | $120.00 | -20.8% | 10/19/2026 |
Casey Woodring J.P. Morgan | Hold | Maintained | $155.00 | +2.2% | 10/16/2026 |
Daniel Brennan TD Cowen | Buy | Maintained | $175.00 | +15.4% | 10/13/2026 |
Lu Li Bank of America Securities | Hold | Maintained | $165.00 | +8.8% | 10/09/2026 |
Michael Ryskin Bank of America Securities | Hold | Maintained | $165.00 | +8.8% | 10/09/2026 |
Luke Sergott Barclays | Hold | Maintained | $160.00 | +5.5% | 10/07/2026 |
Matt Larew William Blair | Buy | Initiated | - | - | 10/05/2026 |
Evie Koslosky Goldman Sachs | Hold | Maintained | $140.00 | -7.7% | 09/20/2026 |
Unknown Analyst CFRA | Hold | Downgraded | - | - | 09/18/2026 |
Unknown Analyst UBS | Hold | Initiated | $140.00 | -7.7% | 09/08/2026 |
Doug Schenkel UBS | Hold | Downgraded | $140.00 | -7.7% | 09/09/2026 |
Paul Knight KeyBanc | Buy | Maintained | $165.00 | +8.8% | 09/04/2026 |
Unknown Analyst KeyBanc | Buy | Maintained | $165.00 | +8.8% | 09/04/2026 |
Dan Leonard RBC Capital | Hold | Initiated | $135.00 | -10.9% | 09/01/2026 |
Vijay Kumar Evercore ISI | Buy | Maintained | $126.00 | -16.9% | 08/05/2026 |
Evan Stampler Wells Fargo | Hold | Maintained | $110.00 | -27.4% | 08/05/2026 |
Unknown Analyst Wells Fargo | Hold | Maintained | $110.00 | -27.4% | 08/05/2026 |
Daniel Arias Stifel Nicolaus | Hold | Reiterated | $110.00 | -27.4% | 08/05/2026 |
Puneet Souda Leerink Partners | Buy | Reiterated | - | - | 07/17/2026 |
Michael Polark Wolfe Research | Hold | Initiated | - | - | 06/01/2026 |
Unknown Analyst Guggenheim | Hold | Reiterated | - | - | 05/11/2026 |
Catherine Ramsey Schulte Robert W. Baird | Buy | Maintained | $117.00 | -22.8% | 05/04/2026 |
Unknown Analyst Goldman Sachs | Hold | Maintained | $95.00 | -37.3% | 04/14/2026 |
Jack Meehan Nephron | Hold | Upgraded | $90.00 | -40.6% | 03/26/2026 |
Brandon Couillard Wells Fargo | Hold | Maintained | $110.00 | -27.4% | 02/03/2026 |
Tycho Peterson Jefferies | Hold | Maintained | $105.00 | -30.7% | 02/02/2026 |
Next call in 10:27:26
Tomorrow, 7:30 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $1.30
Revenue / Est. (USD)
- / 694.74M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|
Revenue | 698.95M | 772.06M | 711.12M | 729.69M |
Cost of goods sold | 324.34M | 350.40M | 323.46M | 312.82M |
Cost of revenue | 324.34M | 350.40M | 323.46M | 312.82M |
Research and development expenses | 50.80M | 58.18M | 57.89M | 48.97M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 227.44M | 208.55M | 241.91M | 243.46M |
Operating expense | 278.23M | 266.73M | 299.80M | 292.43M |
Total operating expenses | 602.58M | 617.12M | 623.26M | 605.25M |
Operating income | 96.37M | 154.93M | 87.86M | 124.44M |
Other non operating income | - | - | - | - |
EBT including unusual items | 55.68M | 91.56M | 49.99M | 63.53M |
EBT excluding unusual items | 76.49M | 133.38M | 65.92M | 105.36M |
Income tax expense | 8.46M | -4.21M | 9.10M | 10.05M |
Effective tax rate | 15.20% | -4.60% | 18.20% | 15.82% |
Other operating expenses | - | - | - | - |
Net income | 46.65M | 98.36M | 40.72M | 51.82M |
Net profit margin | 6.67% | 12.74% | 5.73% | 7.10% |
Earnings per share | 1.18 | 1.70 | 1.06 | 1.41 |
Interest and investment income | 6.92M | 5.75M | 6.30M | 5.26M |
Interest expense | -22.77M | -23.51M | -24.72M | -22.99M |
Net interest expenses | -15.85M | -17.76M | -18.41M | -17.73M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 198.43M | 258.01M | 192.91M | 226.47M |
Gain or loss from assets sale | - | - | -5.07M | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events